Skip to content
DataLookout
Menu

NCT07926334

A Study of BI 4015092, Alone or in Combination With Other Cancer Treatment, in Patients With Advanced Cancer That Has a KRAS G12D Mutation

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Dose escalation (DE) parts: Occurrence of dose limiting toxicities (DLTs) during the primary DLT evaluation period
Timeframe: Up to 3 weeks
Monotherapy expansion part: Objective response (OR)
Timeframe: Up to 36 months
Combination therapy randomized dose optimization (Combi RDO) part: OR
Timeframe: Up to 36 months

Secondary (13)

All trial parts: Occurrence of treatment-emergent adverse events (AEs)
All trial parts: Occurrence of DLTs
All trial parts: Occurrence of drug-related AEs
All trial parts: Occurrence of treatment-emergent serious adverse events (SAEs)
DE part: OR
Show 8 moreShow less
Mono expansion part and Combi RDO part: Duration of response (DoR), based on RECIST v1.1
Mono expansion part and Combi RDO part: Progression free survival (PFS)
Mono expansion part and Combi RDO part: PFS at 6 months (PFS6)
Mono expansion part and Combi RDO part: Clinical benefit (CB)
All trial parts: Disease control (DC), based on RECIST v1.1
All trial parts: Maximum measured concentration of the analyte in plasma (Cmax) (after the first dose in Cycle 1 and 2)
All trial parts: Area under the concentration-time curve over a uniform dosing interval 0 - 24 h (AUC0-24) (Cycle 1) or τ (AUCτ) (Cycle 2) (after first administration in Cycle 1 or Cycle 2)
DE part back fill cohorts: Changes from baseline in the transcript levels of genes controlled by the mitogen-activated protein kinase (MAPK) pathway, such as dual specificity phosphatase 6 (DUSP6)

Arms and interventions

Part A1: Dose escalation for monotherapyExperimental
Part B1: Dose escalation for combination therapyExperimental
Part A2: Monotherapy expansionExperimental
Part B2: Combination therapy, dose optimizationExperimental

Drugs: BI 4015092, Cetuximab

Sites

11 sites in 5 countries

United States 3, Australia 2, Japan 2, South Korea 2, Spain 2